Proand synbiotics in the treatment of intestinal diseases: what effects can we expect?

Cover Page

Cite item

Full Text

Abstract

The relationship between intestinal microbiota and human health is widely recognized. The advent of molecular and genetic diagnostic methods has made it possible to make truly revolutionary discoveries in the field of understanding the role of the digestive tract microbiome. Many studies have proved the association of the composition of microbiota with the development of a number of diseases of the digestive tract, such as inflammatory bowel diseases, functional gastrointestinal disorders and some types of cancer. The food and pharmaceutical industry has presented a huge selection of food products, dietary supplements and medicines containing prebiotic and probiotic components. The use of agents that affect microbiota in the treatment of intestinal diseases in real clinical practice should be carried out strictly in accordance with the indications, in recommended doses.

About the authors

Olga V. Gaus

Omsk State Medical University

Email: gaus_olga@bk.ru
канд. мед. наук, ассистент каф. факультетской терапии Omsk, Russia

Maria A. Livzan

Omsk State Medical University

д-р мед. наук, проф., зав. каф. факультетской терапии Omsk, Russia

References

  1. Jandhyala SM, Talukdar R, Subramanyam C et al. Role of the normal gut microbiota. World J Gastroenterol 2015; 21 (29): 8787-803.
  2. Cresci GA. The gut microbiome: what we do and don't know. Nutr Clin Pract 2015; 30 (6): 734-6.
  3. Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep 2010; 12 (5): 319-30.
  4. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140 (6): 805-20.
  5. He B, Xu W, Santini PA et al. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 2007; 26 (6): 812-26.
  6. Alakomi HL, Skytta E, Saarela M et al. Lactic acid permeabilizes gram-negative bacteria by disrupting the outer membrane. Appl Environ Microbiol 2000; 66 (5): 2001-5.
  7. Velagapudi VR, Hezaveh R, Reigstad CS et al. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res 2010; 51 (5): 1101-12.
  8. Azad MAK, Sarker M, Wan D. Immunomodulatory effects of probiotics on cytokine profiles. Biomed Res Int 2018; 8063647: 2018.
  9. Defois C, Ratel J, Garrait G et al. Food chemicals disrupt human gut microbiota activity and impact intestinal homeostasis as revealed by in vitro systems. Sci Rep 2018; 8 (1): 11006.
  10. Clayton TA, Baker D, Lindon JC et al. Pharmacometabonomic identification of a significant hostmicrobiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A 2009; 106 (34): 14728-33.
  11. Saha JR, Butler VP Jr, Neu HC, Lindenbaum J. Digoxin-inactivating bacteria: identification in human gut flora. Science 1983; 220 (4594): 325-7.
  12. Wallace BD, Wang H, Lane KT et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010; 330 (6005): 831-5.
  13. Dominguez-Bello MG, Costello EK, Contreras M et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A 2010; 107 (26): 11971-5.
  14. Sherman MP, Zaghouani H, Niklas V. Gut microbiota, the immune system, and diet influence the neonatal gut-brain axis. Pediatr Res 2015; 77 (1-2): 127-35.
  15. Zimmer J, Lange B, Frick JS et al. A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. Eur J Clin Nutr 2012; 66: 53-60.
  16. David LA, Maurice CF, Carmody RN et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505 (7484): 559-63.
  17. McDonald D, Hyde E, Debelius JW et al. American gut: an open platform for citizen science microbiome research. mSystems 2018; 3 (3): e00031-18.
  18. Prideaux L, Kang S, Wagner J et al. Impact of ethnicity, geography, and disease on the microbiota in health and inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 2906-18.
  19. Jernberg C, Ldfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J 2007; 1 (1): 56-66.
  20. Ng KM, Ferreyra JA, Higginbottom SK et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 2013; 502 (7469): 96-9.
  21. Chong PP, Chin VK, Looi CY et al. The Microbiome and Irritable Bowel Syndrome - A Review on the Pathophysiology, Current Research and Future Therapy. Front Microbiol 2019; 10: 1136.
  22. Гаус О.В., Ливзан М.А. Синдром раздраженного кишечника: что мы знаем о симптомах сегодня? Consilium Medicum. 2019; 21 (8): 42-8. [Gaus O.V., Livzan M.A. Irritable bowel syndrome: what do we know about symptoms today? Consilium Medicum. 2019; 21 (8): 42-8 (in Russian).]
  23. Ливзан М.А., Гаус О.В., Турчанинов Д.В., Попелло Д.В. Синдром абдоминальнои боли в мо-лодежнои среде: распространенность и факторы риска. Эксперим. и клин. гастроэнтерология. 2019; 170 (10): 12-7.
  24. Sinagra E, Morreale GE, Mohammadian G et al. New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immune-neuroendocrine axis, motility, secretion and beyond. World J Gastroenterol 2017; 23 (36): 6593-627.
  25. Костенко М.Б., Ливзан М.А. Механизмы развития синдрома раздраженного кишечника. Сиб. журн.гастроэнтерологии и гепатологии. 2000;10: 32.
  26. Collins SM. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol 2014; 11: 497-505.
  27. Khan I, Ullah N, Zha L et al. Alteration of the gut microbiota in inflammatory bowel disease (IBD): cause of consequence? IBD treatment targeting the gut microbiome. Pathogens 2019; 8 (3): 126.
  28. Mentella MC, Scaldaferri F, Pizzoferrato M et al. Nutrition, IBD and gut microbiota: a review. Nutrients 2020; 12 (4): 944.
  29. Ливзан М.А., Мозговой С.И., Кононов А.В. Гастрит после эрадикации Helicobacter pylori -простые следы или серьезные последствия? Лечащий врач. 2011; 7: 7.
  30. Tilg G, Schmiderer A, Djanani A. Gut microbiom - immune crosstalk affects progression of cancer. Transl Gastroenterol Hepatol 2018; 3: 34.
  31. Глобальные практические рекомендации Всемирной Гастроэнтерологической Организации. Пробиотики и пребиотики. https://www.worldgastroenterology.org/UserFiles/file/guidelines/pro-biotics-and-prebiotics-russian-2017.pdf
  32. Harper A, Naghibi M, Garcha D. The role of bacteria, probiotics and diet in irritable bowel syndrome. Foods 2018; 7 (2): 13.
  33. Kankaanpaa P, Sutas Y Salminen S, Isolauri E. Homogenates derived from probiotic bacteria provide down-regulatory signals for peripheral blood mononuclear cells. Food Chemistry 2003; 83 (2): 269-77.
  34. Bodera P, Chcialowski A. Immunomodulatory effect of probiotic bacteria. Recent Pat Inflamm Allergy Drug Discov 2009; 3 (1): 58-64.
  35. Maroof H, Mohammad Hassan Z, Mohabati Mobarez A, Azimi Mohamadabadi M. Lactobacillus acidophilus could modulate the immune response against breast cancer in murine model. J Clin Immunol 2012; 32: 1353-9.
  36. Ливзан М.А., Костенко М.Б. Место пробиотической терапии в лечении и профилактике ан-тибиотик-ассоциированной диареи. Лечащий врач. 2010; 10: 83.
  37. Ouwehand AC, DongLian C, Weijian X et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: A randomized dose response study. Vaccine 2014; 2 (4): 458-63.
  38. Goldenberg JZ, Yap C, Lytvyn L et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2017; 12: CD006095.
  39. Parker EA, Roy T, D’Adamo CR, Wieland LS. Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration. Nutrition 2018; 45 (2018): 125-34.
  40. Li B, Liang L, Deng H et al. Efficacy and safety of probiotics in irritable bowel syndrome: a systematic review and meta-analysis. Front Pharmacol 2020; 11: 332.
  41. Ахмедов В.А., Орлов И.Н., Гаус О.В. Современные методы реабилитации пациентов с синдромом раздраженного кишечника. Терапия. 2017; 3 (13): 49-55.
  42. Connel M, Shin A, James-Stevenson T et al. Systematic review and meta-analysis: efficacy of patented probiotic, VSL#3, in irritable bowel syndrome. Neurogastroenterol Motil 2018; 30 (12): e13427.
  43. Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulatio in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol 2018; 18 (1): 71.
  44. Sun J, Wang F, Hu X et al. Clostridium butyricum attenuates chronic unpredictable mild stress-induced depressive-like behavior in mice via the gut-brain axis. J Agric Food Chem 2018; 66 (31): 8415-21.
  45. Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M et al. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. Nutrition 2016; 32 (3): 315-20.
  46. Rao AV, Bested AC, Beaulne TM et al. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog 2009; 1 (1): 6.
  47. Wallace CJK, Milev R. The effects of probiotics on depressive symptoms in humans: a systematic review. Ann Gen Psychiatry 2017; 16 (1): 14.
  48. Romijn AR, Rucklidge JJ. Systematic review of evidence to support the theory of psychobiotics. Nutr Rev 2015; 73 (10): 675-93.

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies